cfDNA在胰腺癌中的诊断价值

目的 探讨cfDNA在胰腺癌中的诊断价值。方法 选取467例胰腺癌患者和129例健康对照受试者，采用QuantiDNA Direct cfDNA Test（DiaCarta）试剂盒检测cfDNA浓度。采用Mann-Whitney U检验比较不同组间cfDNA浓度差异，卡方检验分析cfDNA与胰腺癌病理资料的关系。ROC曲线评估诊断效能。结果 胰腺癌患者cfDNA水平显著高于健康对照组（20.85 vs. 15.15 ng/ml, P=0.0027）。cfDNA在胰腺癌中的阳性率高于健康对照组（77.73% vs. 59.68%）。 cfDNA、CEA和CA19-9作为诊断标志物的敏感度分别为62.65%、64.04%和60.32%，特异性分别为61.05%、70.53%和87.37%。cfDNA联合检测CEA和CA19-9敏感度为77.26%，特异性为53.58%。cfDNA、CEA、CA19-9和联合检测曲线下面积分别为0.62、0.67、0.74和0.67。结论 cfDNA在胰腺癌患者中水平升高，可作为胰腺癌潜在的辅助诊断标志物。

Diagnostic Value of cfDNA in Pancreatic Cancer

Objective To explore the diagnostic value of cfDNA in pancreatic cancer. Methods A total of 467 patients with pancreatic cancer and 129 healthy controls were enrolled. cfDNA concentration was detected using the QuantiDNA Direct cfDNA Test (DiaCarta) kit. Mann-Whitney U test was used to compare cfDNA concentration between different groups, and Chi-square test was used to analyze the relationship between cfDNA and pathological data of pancreatic cancer. Diagnostic efficacy was evaluated by ROC analysis. Results The cfDNA level of patients with pancreatic cancer was significantly higher than that of healthy controls (20.85 vs. 15.15 ng/ml, P=0.0027). The positive rate of cfDNA in pancreatic cancer was higher than that in healthy controls (77.73% vs. 59.68%). The sensitivity levels of cfDNA, CEA, and CA19-9 as diagnostic markers were 62.65%, 64.04%, and 60.32%, and their specificity levels were 61.05%, 70.53%, and 87.37%, respectively. The sensitivity and specificity of the combined detection were 77.26% and 53.58% respectively. The areas under the curve of cfDNA, CEA, CA199, and combined detection were 0.62, 0.67, 0.74, and 0.67, respectively. Conclusion cfDNA is elevated in patients with pancreatic cancer and may serve as an effective marker for its diagnosis.